Real-time Estimate
Cboe BZX
09:31:55 02/05/2024 pm IST
5-day change
1st Jan Change
259.3
USD
+1.64%
+10.04%
+18.07%
This article is reserved for members
Not a member ?
Free registration
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating
09:18pm
MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating
07:29pm
MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024
01/05
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell
01/05
MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M
01/05
MT
United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing
24/04
MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says
23/04
MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing
20/04
MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing
18/04
MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing
16/04
MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing
12/04
MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing
10/04
MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing
06/04
MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing
05/04
MT
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension
01/04
MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling
01/04
DJ
United Therapeutics Corporation Announces Extension of Credit Agreement
30/03
CI
United Therapeutics Insider Sold Shares Worth $7,375,339, According to a Recent SEC Filing
28/03
MT
United Therapeutics Corporation announces an Equity Buyback for $1,000 million worth of its shares.
26/03
CI
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing
26/03
MT
United Therapeutics Authorizes Accelerated $1 Billion Stock Buyback Through Citigroup
25/03
MT
United Therapeutics Corporation authorizes a Buyback Plan.
24/03
CI
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing
23/03
MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing
22/03
MT
United Therapeutics Insider Sold Shares Worth $7,209,192, According to a Recent SEC Filing
16/03
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
More about the company
Last Close Price
255.1
USD
Average target price
289.4
USD
Spread / Average Target
+13.41%
Consensus
1st Jan change
Capi.
+18.07% 11.32B +19.69% 42.68B -3.21% 42.4B +45.32% 40.04B -6.20% 28.31B +7.48% 24.94B -20.05% 18.96B +30.21% 12.3B -2.77% 11.95B -2.67% 11.55B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1